Default company panoramic image

BNOAT Oncology, Inc.

Our goal is to commercialize a Trojan Horse, non-toxic, anti-tumor drug for the ever growing veterinary oncology market.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Akron, OH, USA
  • Currency USD
  • Employees 6
  • Website

Company Summary

BNOAT Oncology, Inc. is an early stage oncology research and development company focused on bringing its lead candidate, nitrosylcobalamin (NO-Cbl), to the veterinary market. BNOAT Oncology, Inc. is seeking full approval for the veterinary use of NO-Cbl through the FDA's Minor Use/Minor Species (MUMS) regulatory pathway.


  • Default avatar
    Joseph A Bauer, Ph.D.
    President and Chief Executive Officer

  • Default avatar
    Annette M. Sysel, DVM, MS
    Vice President

  • Default avatar
    Michael J. Dunphy, Ph.D.
    Director of Laboratory Operations

  • Default avatar
    Joseph A Lupica, Ph.D.
    Project Manager

  • Default avatar
    Amy Heston, Ph.D.
    Project Manager


  • Default avatar
    Weisun Rao, JD, PhD, Greenberg Traurig, LLP
    Default avatar
    Frank J. Monaco, CPA/ABV, MT, CVA; 415 Group